Janssen considers itself a world leader in neuroscience research and development of transformational treatments. Over 60 years ago, our founder, Dr Paul Janssen, developed some of the first psychiatric treatments and we have continued to innovate in the field of schizophrenia, bipolar disorder, depressive disorders and dementia. Today, we are focused on leading the neuroscience revolution to predict and pre-empt devastation cause by neuropsychiatric and neurodegenerative diseases and are developing medicines for disorders of cognition, mood, ADHD, epilepsy, Alzheimer's disease and schizophrenia.
We are involved in a large number of initiatives to support people affected by mental illness and in particular, to reduce the stigma of mental health in the community. Our strategy is to harness the best science in the world, whether from our own laboratories or through strategic relationships and collaborations with academia, biotech and other pharmaceutical companies. We have helped lead and have invested in the global Dementia Discovery Fund and are involved in many other public-private collaborations.